Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study)

Fig. 1

Study population for the ST cohort. *Five patients were excluded from the analysis: four due to deviation from the eligibility criteria and one because of a duplicated patient record. †Of these patients, 261 left the study before the 3-month follow-up visit but were reviewed for data collection. ‡Patients who left the study prematurely and were not followed up were comparable with the followed-up patients in terms of age, sex, tumour type and stage, comorbidities, and CT treatments. They had significantly more prior episodes of neutropenia (p=0.04) and a worse performance score (p<0.01) at inclusion compared with the followed-up patients. CT chemotherapy, ST solid tumour

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us